Egalet Lines Up Cash In Deal With Japan’s Shionogi Ahead Of IPO
This article was originally published in PharmAsia News
Executive Summary
The specialty pharma will receive $10 million upfront from Shionogi in exchange for rights to multiple oral abuse-deterrent hydrocodone opioid products. The Japanese pharma also agreed to buy $15 million in stock to close with Egalet’s IPO.